XML 48 R24.htm IDEA: XBRL DOCUMENT
v3.26.1

Basis of Presentation and Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Accounting Policies [Abstract] |
Summary of Significant Expense Categories Regularly Reviewed CODM | The table below summarizes the significant expense categories regularly reviewed by the CODM:
|  | Years Ended December 31, |
|  | 2025 |  |  | 2024 |
Collaboration revenue |  | $ | 7,945,753 |  |  | $ | 3,554,061 |
Less: |  |  |  |  |  |
Research and development expenses (a): |  |  |  |  |  |
Clinical product candidates |  |  | 4,873,971 |  |  |  | - |
Preclinical product candidates |  |  | 6,509,360 |  |  |  | 8,313,290 |
Sponsored research |  |  | 908,928 |  |  |  | 556,265 |
Internal research and development expenses, including stock-based compensation |  |  | 4,442,290 |  |  |  | 2,996,099 |
Total research and development expenses |  |  | 16,734,549 |  |  |  | 11,865,654 |
General and administrative expenses: |  |  |  |  |  |
Employee related costs |  |  | 3,100,930 |  |  |  | 2,685,556 |
Stock-based compensation |  |  | 2,802,173 |  |  |  | 1,588,667 |
Other general and administrative expenses (b) |  |  | 5,546,363 |  |  |  | 4,611,534 |
Total general and administrative expenses |  |  | 11,449,466 |  |  |  | 8,885,757 |
In-process research and development |  |  | 2,289,602 |  |  |  | 25,000 |
Depreciation |  |  | 27,361 |  |  |  | 27,361 |
Other income |  |  | (1,332,207 | ) |  |  | (1,648,637 | )
Pre-tax loss |  |  | (21,223,018 | ) |  |  | (15,601,074 | )
Income tax benefit |  |  | (3,089 | ) |  |  | 720,287 |
Net loss |  | $ | (21,226,107 | ) |  | $ | (14,880,787 | )
(a) External research and development expenses include: fees paid to CROs, CMOs and research laboratories, process development, manufacturing and clinical development activities. Any internal research and development expenses associated with clinical product candidates are captioned as internal research and development expenses. (b) Other general and administrative costs include professional fees, investor relation costs, taxes, licenses, and insurance.
Summary of Changes in Deferred Revenue | The following table summarizes the changes in deferred revenue:
|  | Years Ended December 31, |
|  | 2025 |  |  | 2024 |
Beginning balance |  | $ | 1,793,733 |  |  | $ | 1,497,794 |
Deferral of revenue |  |  | 1,703,454 |  |  |  | 780,749 |
Recognition of unearned revenue |  |  | (1,249,207 | ) |  |  | (484,810 | )
Ending balance |  | $ | 2,247,980 |  |  | $ | 1,793,733 |
Schedule of Dilutive Securities Excluded from Computation of Diluted Weighted-Average Shares of Common Stock Outstanding | The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:
|  | As of December 31, |  |
|  | 2025 |  |  | 2024 |  |
Common stock warrants |  |  | 822,260 |  |  |  | 815,677 |  |
Stock options |  |  | 2,971,238 |  |  |  | 2,228,658 |  |
|  |  | 3,793,498 |  |  |  | 3,044,335 |  |

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration